FDA Decision Strains Hims & Hers – Focus on Quarterly Numbers This Evening
Reading Time: 3 minutes
• Production of GLP-1 Analogues Ends: With the end of the Wegovy supply shortage, Hims & Hers must cease production by May 2025 – a heavy blow for the revenue-rich weight loss segment. • Anticipation Ahead of Q4 Numbers: Despite a share price drop of 25%, investors hope for strong quarterly results and details on the future strategy in the weight loss medication sector. The US Food and Drug Administration (FDA) announced on Friday, February 21, 2025, that the supply shortage for the popular weight loss drug Wegovy from Novo Nordisk...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
